Patents Examined by Hasan Ahmed
  • Patent number: 10154965
    Abstract: An oral osmotic pharmaceutical delivery system comprises a highly water-soluble drug exhibiting an erratic or an incomplete release profile when formulated in an elementary osmotic pump delivery system and at least one release enhancing agent.
    Type: Grant
    Filed: May 24, 2016
    Date of Patent: December 18, 2018
    Assignee: United Therapeutics Corporation
    Inventors: Argaw Kidane, Padmanabh P Bhatt
  • Patent number: 10118947
    Abstract: The invention describes peptide ligands specific for human plasma Kallikrein.
    Type: Grant
    Filed: April 11, 2014
    Date of Patent: November 6, 2018
    Assignee: BicycleRD Limited
    Inventors: Daniel Paul Teufel, Catherine Stace, Edward Walker, John Tite
  • Patent number: 10046056
    Abstract: Several embodiments of the present disclosure relate to glycotargeting therapeutics that are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent. In several embodiments, the compositions are configured to target the liver and deliver antigens to which tolerance is desired. Methods and uses of the compositions for induction of immune tolerance are also disclosed herein.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: August 14, 2018
    Assignee: École Polytechnique Fédérale de Lausanne (EPFL)
    Inventors: Jeffrey A. Hubbell, David Scott Wilson
  • Patent number: 10046092
    Abstract: The present invention is related to scoring or cutting balloon catheters carrying at least on a portion of their surface at least one oxidation-insensitive drug or oxidation-insensitive polymer-free drug preparation and at least one lipophilic antioxidant at a ratio of 3-100% by weight of the at least one lipophilic antioxidant in relation to 100% by weight of the drug, wherein the at least one oxidation-insensitive drug is selected of taxanes, thalidomide, statins, corticoids and lipophilic derivatives of corticoids, and the at least one lipophilic antioxidant is selected of nordihydroguaiaretic acid, resveratrol and propyl gallate.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: August 14, 2018
    Assignee: The SPECTRANETICS CORPORATION
    Inventors: Ulrich Speck, Madeleine Caroline Berg
  • Patent number: 10034913
    Abstract: Provided are peptide sequences derived from prostate serum antigen (PSA). The peptides are provided in cyclic and linear form. Methods for using the peptides for inhibition of angiogenesis, such as angiogenesis in a tumor, are provided.
    Type: Grant
    Filed: August 4, 2015
    Date of Patent: July 31, 2018
    Assignee: Health Research, Inc.
    Inventors: Kailash C. Chadha, Gary J. Smith
  • Patent number: 10034829
    Abstract: A semi-permanent mascara composition for use on eyelashes and/or eyelids that includes from 17% to 30%, by weight, of a film former selected from the group consisting of tall oil glyceride, pentaerythrityl rosinate, glyceryl rosinate, and the hydrogenated versions and mixtures thereof. Further there is from 0.1% to 14%, by weight, of a colorant and from 10% to 15%, by weight, of disteardimonium hectorite, and less than about 3% of wax. The semi-permanent mascara composition is long lasting and has excellent wear characteristics.
    Type: Grant
    Filed: October 17, 2011
    Date of Patent: July 31, 2018
    Assignee: Noxell Corporation
    Inventors: James Herman Dempsey, Thomas Elliot Rabe
  • Patent number: 10029011
    Abstract: A liquid composition comprising a GLP-1 agonist or/and a pharmacologically tolerable salt thereof, an insulin or/and a pharmacologically tolerable salt thereof, and, optionally, at least one pharmaceutically acceptable excipient, wherein the composition comprises methionine, as add-on therapy with metformin where appropriate.
    Type: Grant
    Filed: November 11, 2010
    Date of Patent: July 24, 2018
    Assignee: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Annika Hagendorf, Gerrit Hauck, Werner Mueller, Isabell Schoettle, Verena Siefke-Henzler, Katrin Tertsch
  • Patent number: 10017540
    Abstract: Cyclic peptides represented by (Formula 1) selectively bind the oncoprotein K-Ras G12D in vitro and in cellulo, where Z1 and Z2 are each L-propargylglycine (Pra), azidoornithine (OrnN3), or L-azidolysine (Az4), and V1-V2-V3-V4-V5 is an amino acid variable region having a sequence selected from the group consisting of SEQ ID NOs: 1-20.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: July 10, 2018
    Assignee: California Institute of Technology
    Inventors: Ryan K. Henning, Ashwin N. Ram, Samir Das, Arundhati Nag, James R. Heath
  • Patent number: 10010647
    Abstract: A wound dressing having anti-microbial activity comprises a first fiber capable of bonding with silver (1) cations. The wound dressing comprises a blend of the first fiber to which silver (1) cations are bonded and a second fiber which is substantially free from silver. The wound dressing comprises from 0.01 to 5.0 percent by weight of silver (1) cations, based on the weight of fiber.
    Type: Grant
    Filed: May 24, 2016
    Date of Patent: July 3, 2018
    Assignee: CONVATEC TECHNOLOGIES INC.
    Inventor: David Malcolm Woods
  • Patent number: 10000542
    Abstract: The invention relates to a derivative of a GLP-1 analogue, which analogue comprises a first K residue and a second K residue, at positions corresponding to position 26, and 37, respectively, of GLP-1(7-37) (SEQ ID NO: 1), and a maximum of eight amino acid changes as compared to GLP-1(7-37); which derivative comprises two protracting moieties attached to said first and second K residue, respectively, via a linker, wherein the protracting moiety is selected from Chem. 1: HOOC—(CH2)x—CO—*, and Chem. 2: HOOC—C6H4—O—(CH2)y—CO—*, in which x is an integer in the range of 8-16, and y is an integer in the range of 6-13; and the linker comprises Chem. 3: *—NH—(CH2)q—CH[(CH2)w—NR1R2]—CO—*, which is connected at its CO—* end to the epsilon amino group of the first or the second K residue of the GLP-1 analogue, and wherein q is an integer in the range of 0-5, R1 and R2 independently represent *—H or *—CH3, and w is an integer in the range of 0-5; or a pharmaceutically acceptable salt, amide, or ester thereof.
    Type: Grant
    Filed: May 2, 2013
    Date of Patent: June 19, 2018
    Assignee: Novo Nordisk A/S
    Inventors: Jacob Kofoed, Patrick W. Garibay, Jesper Lau
  • Patent number: 9993424
    Abstract: The present invention relates to a process for the preparation of an intravaginal matrix drug delivery device. The process comprises the steps of combining at least one therapeutic agent in a therapeutically effective amount with at least one biocompatible elastomeric polymer to form a mix; curing said mix in a mold having a shape of said intravaginal drug delivery device, to form a polymer matrix; and maturing said polymer matrix to form the intravaginal drug delivery device. The maturing step alters the release rate characteristics of a device prepared in accordance with the process of the invention.
    Type: Grant
    Filed: March 27, 2003
    Date of Patent: June 12, 2018
    Assignee: Allergan Pharmaceuticals International Limited
    Inventors: Brendan Muldoon, Colin Lorimer, Claire Gilligan
  • Patent number: 9994617
    Abstract: The invention describes a method for selecting a polypeptide ligand having a desired level of specificity for a target, wherein the polypeptide ligand comprises a polypeptide comprising at least three reactive groups, separated by at least two loop sequences, and a molecular scaffold which forms covalent bonds with the reactive groups of the polypeptide such that at least two polypeptide loops are formed on the molecular scaffold, comprising (i) screening at least two different sets of polypeptide ligands against the target, and selecting one or more ligands from each library which interact with the target; (ii) comparing the activity of the selected ligands with one or more paralogues or orthologues of the target; and (iii) further selecting one or more ligands according to their activity towards said one or more paralogues or orthologues; wherein said two or more different sets of ligands differ in the length of the polypeptide loops formed on the molecular scaffold.
    Type: Grant
    Filed: October 8, 2012
    Date of Patent: June 12, 2018
    Assignee: BicycleRD Limited
    Inventors: John Tite, Edward Walker, Catherine Stace, Christian Heinis
  • Patent number: 9988420
    Abstract: Disclosed herein are novel cytotoxic peptides of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel cytotoxic peptide linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: June 5, 2018
    Assignee: Novartis AG
    Inventors: Bernhard Hubert Geierstanger, Jan Grunewald, Weijia Ou, Tetsuo Uno, Yongqin Wan, Xing Wang, Yunho Jin
  • Patent number: 9974888
    Abstract: The present invention is related to a medical device carrying at least on a portion of its surface at least one oxidation-insensitive drug or oxidation-insensitive polymer-free drug preparation and at least one lipophilic antioxidant at a ratio of 3-100% by weight of the at least one antioxidant in relation to 100% by weight of the drug, wherein the at least one oxidation-insensitive drug is selected of taxanes, thalidomide, statins, corticoids and lipophilic derivatives of corticoids, and the at least one lipophilic antioxidant is selected of nordihydroguaiarectic acid, resveratrol and propyl gallate, and wherein scoring or cutting balloons as medical devices are excluded.
    Type: Grant
    Filed: November 3, 2010
    Date of Patent: May 22, 2018
    Assignee: INNORA GmbH
    Inventors: Ulrich Speck, Madeleine Caroline Berg
  • Patent number: 9956426
    Abstract: Provided herein are lanthanide-containing upconverting nanoparticles, methods of their preparation, compositions, and methods of using the same. The polymers and compositions provided herein may be used, for example, in photodynamic therapy.
    Type: Grant
    Filed: February 26, 2015
    Date of Patent: May 1, 2018
    Inventor: Amol Punjabi
  • Patent number: 9951120
    Abstract: Methods for treating type two diabetes mellitus in a subject in need thereof and pharmaceutical compositions for the treatment of type two diabetes mellitus are disclosed, wherein the methods and compositions of the invention are based on the use of non-glycosylated apolipoprotein A-IV produced by a protein expression system, such as a bacterial expression system. Also disclosed are methods for substantially restoring glucose tolerance in a subject in need thereof to a normal level and methods for lowering blood glucose levels in a subject in need thereof based on administering non-glycosylated apolipoprotein A-IV produced by a protein expression system.
    Type: Grant
    Filed: November 21, 2012
    Date of Patent: April 24, 2018
    Assignee: University of Cincinnati
    Inventors: Patrick Tso, Fei Wang, Sean Davidson
  • Patent number: 9936701
    Abstract: The invention relates to pyrrolone compounds of the formula (I) wherein X, Rb, Rc, R1, R2 and R3 are as defined in the specification. Furthermore, the present invention relates to processes and intermediates for making compounds of formula (I), to herbicidal compositions comprising these compounds and to methods of using these compounds to control plant growth.
    Type: Grant
    Filed: May 1, 2014
    Date of Patent: April 10, 2018
    Assignees: Syngenta Limited, Syngenta Participations AG
    Inventors: James Alan Morris, Shuji Hachisu, William Guy Whittingham, Anne Jaqueline Dalencon, Jutta Elisabeth Boehmer, Mangala Phadte, Ravindra Sonawane, Adrian Longstaff, Alan John Dowling, Timothy Robert Desson, Sitaram Pal, Janice Black, Swarnendu Sasmal, Guruprasad Narashimh Sawant, Srinivas Reddy Purumandla, Sujit Kumar Ghorai
  • Patent number: 9936692
    Abstract: Nanoengineered particulate coatings (NPCs) comprise a multiplicity of particulate hosts that are infused with a nanophase comprising a surfactant and at least one guest. The particulate hosts can be clay particles, the surfactant can be a cationic surfactant, and the guest can be an insect repellant. For example, montmorillonite particles infused with hexadecyl trimethyl ammonium bromide and garlic oil form NPCs that may be used to form an emulsion or suspension for spraying on citrus trees to repel Asian Citrus Psyllid.
    Type: Grant
    Filed: February 14, 2013
    Date of Patent: April 10, 2018
    Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
    Inventors: Parvesh Sharma, Aarthi Narayanan, Hassan E. El-Shall, Brij M. Moudgil
  • Patent number: 9925156
    Abstract: The disclosure provides oral cysteamine and cystamine formulations useful for treating cystinosis and neurodegenerative diseases and disorders. The formulations provide controlled release compositions that improve quality of life and reduced side-effects.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: March 27, 2018
    Assignee: The Regents of the University of California
    Inventors: Ranjan Dohil, Jerry Schneider
  • Patent number: 9925157
    Abstract: The disclosure provides oral cysteamine and cystamine formulations useful for treating cystinosis and neurodegenerative diseases and disorders. The formulations provide controlled release compositions that improve quality of life and reduced side-effects.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: March 27, 2018
    Assignee: The Regents of the University of California
    Inventors: Ranjan Dohil, Jerry Schneider